Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Accumulated Expenses (2018 - 2025)

X4 Pharmaceuticals' Accumulated Expenses history spans 8 years, with the latest figure at $18.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 19.13% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $18.6 million, down 19.13%, while the annual FY2025 figure was $18.6 million, 19.13% down from the prior year.
  • Accumulated Expenses reached $18.6 million in Q4 2025 per XFOR's latest filing, up from $16.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $23.0 million in Q4 2024 to a low of $6.9 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $13.3 million, with a median of $12.7 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 85.03% in 2021, then tumbled 35.76% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $7.9 million in 2021, then soared by 52.91% to $12.0 million in 2022, then grew by 6.5% to $12.8 million in 2023, then skyrocketed by 79.5% to $23.0 million in 2024, then dropped by 19.13% to $18.6 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Accumulated Expenses are $18.6 million (Q4 2025), $16.7 million (Q3 2025), and $13.1 million (Q2 2025).